Loading...
Searching Database & Compiling the results...
This process involves analyzing complex genetic data and may take a moment.
PDX model details
| PDX ID | 472M |
|---|---|
| Host Strain(and Source) | NSG Source: Monash University |
| Host Strain Immune system Humanized | NO |
| Host Type | Testosterone supplemented |
| Graft Site | Subcutaneous |
| Current Generation (* indicates number of generations grown in Castrate host) |
20 |
| Average PDX Generation Time (days +/- SEM) | 54 ± 7 |
| Tumour preparation | Tumor solid |
| Tumour Characterization Technology | Histology, IHC, STR profiling, targeted DNA sequencing, RNAseq |
| Tumour confirmed not to be of Mouse/EBV origin | Yes; negative for CD45 and/or positive for human CK8/18 and/or human mitochondria by IHC |
| Passage QA performed | Routine QA every 2-3 passages |
| Associated meta data | |
| PDX model availability | Yes (fixed, frozen) |
| Governance restriction for distribution | Available to investigators with appropriate ethics approvals, approved EOI from MURAL committee, and material transfer agreements |
| Pubmed ID | 34413304 |
| Markers | 472M |
|---|---|
| AR | N |
| PSA | N |
| PSMA | N |
| NE | Y |
| ERG | N |
This table displays curated CNVs
| PDX ID | Gene Symbol | CNV Log2 | CNV Copy | CNV Call | Experiments name | Platform | Reference genome |
|---|---|---|---|---|---|---|---|
| 472M | BRCA1 | -0.945 | 1.039 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 472M | NCOR1 | -1.008 | 0.995 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 472M | TP53 | -1.088 | 0.941 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 472M | FANCA | -1.013 | 0.991 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 472M | ZFHX3 | -1.013 | 0.991 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 472M | CDH1 | -1.013 | 0.991 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 472M | PTEN | -0.992 | 1.005 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 472M | PTEN | -1.935 | 0.523 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 472M | CDKN1B | -1.041 | 0.972 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 472M | RB1 | -27.780 | 8.680e-09 | Homdel | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 472M | GNAS | 0.561 | 2.950 | Gain | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 472M | PIK3R2 | 0.515 | 2.858 | Gain | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 472M | KEAP1 | 0.515 | 2.858 | Gain | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 472M | MYC | 0.494 | 2.816 | Gain | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 472M | CHD7 | 0.594 | 3.020 | Gain | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 472M | IGF2R | 0.506 | 2.840 | Gain | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 472M | SETDB1 | 0.512 | 2.852 | Gain | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
Clinical Information
| Sample Number | 472M |
|---|---|
| Sample Site | Left ilium |
| Sample source | Biopsy |
| Pathology Tumour Diagnosis | None |
| Gleason Score | None |
| Primary Gleason Score | None |
| Secondary Gleason Score | None |
| Tertiary Gleason Score | None |
| ISUP Grade Group | |
| Tumour Grade | |
| D'Amico Risk Classification | |
| Tumour Volume (in cc) | 0.0 |
| Treatment Prior to Specimen Collection | ADT, docetaxel |
Patient Information
| Patient Number | 472 |
|---|---|
| Sex | Male |
| Diagnosis | Prostate Cancer |
| PSA at diagnosis (ng/mL) | 630 |
| Consent to share data | Yes, subject to ethical review |
| Patient Tumour Collection (Current Model) | |
|---|---|
| Tumour sample ID | 472M |
| Patient Age (binned in 5 year age groups) | 50-54 |
This table displays curated sequence variants
| PDX ID | Gene Symbol | Total Read Depth | Alternate Frequency | Consequence | Exon | GnomAD AF | CADD PHRED score | ClinVar significance | Platform | Experiments Name | Reference | Library Type | Instrument Type |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 472M | SRC | 717 | 0.66 | Missense variant | '12/14 | 8.15E-06 | 25.1 | - | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
| 472M | GPR158 | 720 | 0.58 | Stop gained | '11/11 | 8.19E-06 | 36 | - | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
| 472M | CTNNB1 | 614 | 0.49 | Missense variant | '3/15 | 4.07E-06 | 28.6 | Pathogenic/likely pathogenic, other | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
No information in Gene expression
No information in Drug dosing Table